Overview

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Status:
Not yet recruiting
Trial end date:
2024-05-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MYK-224 in participants with obstructive Hypertrophic Cardiomyopathy (oHCM)
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb